MiNK Therapeutics, Inc., a biopharmaceutical company focused on allogeneic invariant natural killer T (iNKT) cell therapies, announced the publication of a peer-reviewed article in Frontiers in ...
NEW YORK - MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biotech company with a market capitalization of $161.86 million, announced Tuesday the publication of a peer-reviewed article in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback